论文部分内容阅读
淋巴因子激活杀伤细胞(lymphokine activated killer cell,LAK细胞)是近年来发现的又一类重要的免疫活性细胞,它具有自然杀伤细菌(NK)和TC细胞所不可比拟的作用:①细胞来源有保证(LAK细胞可在体外大量扩增);②非特异性作用(LAK细胞勿需用肿瘤细胞预先致敏),同时重组IL-2(rIL-2)已投入批量生产和产品供应,这一切为IL-2/LAK治疗的临床应用奠定了基础。IL-2/LAK治疗恶性肿瘤的报道日益增多。为了探讨该疗法的临床意义,我们对35例根治术后消化道恶性肿瘤病人应用该疗法,对患者术后(治疗前)及治疗后外围血中血清IL～2、可溶性IL-2R含量及T细胞亚群的水平进行了测定,现报告如下。
Lymphokine activated killer cells (LAK cells) are another important class of immunocompetent cells discovered in recent years. They have the unparalleled effects of natural killer bacteria (NK) and TC cells: 1 The cell source is guaranteed (LAK cells can be massively amplified in vitro); 2 non-specific effects (LAK cells do not require pre-sensitization with tumor cells), while recombinant IL-2 (rIL-2) has been put into mass production and product supply, all of which is IL The foundation of the clinical application of -2/LAK treatment. There have been increasing reports of IL-2/LAK treatment of malignant tumors. In order to explore the clinical significance of this therapy, we applied this therapy to 35 patients with radically treated postoperative gastrointestinal malignancies. Serum IL-2, soluble IL-2R levels, and T were measured in patients after surgery (before treatment) and after treatment. The level of cell subpopulations was measured and is reported below.